Drug intelligence / Profile preview

MAAT034

Development stage: Preclinical
Lead developer: MaaT Pharma
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

MAAT034 is a next-generation, donor-independent, full ecosystem synthetic microbiome therapy developed by MaaT Pharma. It is the first candidate from the company's proprietary MET-C platform and is designed to optimize intestinal microbiome functions prior to and during immunotherapy in major oncology indications. The therapy aims to improve patient responses to immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-PD-L1 agents by restoring gut barrier integrity, modulating immune responses, and enhancing T cell activation. Preclinical studies have shown that MAAT034 effectively engrafts in the gut, increases production of key microbial-derived metabolites (including short-chain fatty acids, secondary bile acids, and tryptophan derivatives), improves gastrointestinal physiology, and significantly potentiates anti-tumor effects when combined with ICIs. The product is being developed for use as a tumor-agnostic adjunctive therapy across various cancer types.

Beyond the preview

Go deeper on MAAT034.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAAT034.

Explore the full profile